Edema News and Research

RSS

Edema means swelling caused by fluid in your body's tissues. It usually occurs in the feet, ankles and legs, but it can involve your entire body.

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

Bristol-Myers Squibb Company and AstraZeneca today announced results from an investigational Phase 3b clinical study in which the addition of ONGLYZA (saxagliptin) 5 mg to ongoing insulin therapy (with or without metformin) maintained reductions of blood sugar levels (glycosylated hemoglobin levels, or HbA1c) in adult patients with type 2 diabetes compared to the addition of placebo (with or without metformin) from 24 to 52 weeks.

16 Sep 2011

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

The Max Planck Society (Max-Planck-Gesellschaft), Germany's leading basic research organization, announced today that it has signed with Fovea Pharmaceuticals, the Ophthalmology Division of Sanofi, a research collaboration and license agreement to identify and develop innovative solutions for restoring vision in patients suffering from diseases affecting the retina.

16 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Lucentis receives Health Canada approval to treat vision loss from DME

Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from diabetic macular edema, one of the major causes of adult vision loss and an important complication of the growing epidemic of diabetes.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Astellas Pharma Inc. today announced the submission of a New Drug Application and Market Authorisation Application for mirabegron to the U.S. Food and Drug Administration and the European Medicines Agency.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

KalVista raises £8 million in series A round of funding

KalVista Pharmaceuticals, a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences.

23 Aug 2011

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

Following a priority review, Health Canada has approved Lucentis (ranibizumab) as a treatment for vision loss resulting from retinal vein occlusion (RVO). This makes Lucentis the first approved treatment of its class in Canada for this debilitating condition. Patients will now have access to a treatment that is proven to be effective and has an established safety profile.

18 Aug 2011

HSS, pSivida enter orthopedic evaluation agreement

Drug delivery company pSivida Corp. today announced it has entered into an evaluation agreement with Hospital for Special Surgery (HSS), a world leader in orthopedics, rheumatology and rehabilitation, to investigate pSivida's drug delivery technologies in orthopedics.

17 Aug 2011

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

Dyax Corp. announced today treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema.

4 Aug 2011

NIH-funded study to assess biomarkers in the blood of TBI patients

Biomarkers in the bloodstream could provide physicians with a quick and accurate method of assessing the severity of traumatic brain injury (TBI) and helping deliver and monitor the results of therapies, such as progesterone treatment.

4 Aug 2011

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application.

4 Aug 2011

Conference to focus on connection between fluid balance and hypertension

Each day we consume liquids in order to keep hydrated and maintain our body's fluid balance. But just as a water balloon can get overtaxed by too much liquid, the human body is negatively affected when it retains fluids because it is unable to eliminate them properly. One of the key variables influencing how much fluid we hold in our bodies is ordinary table salt.

3 Aug 2011

Researchers awarded $12M to study pathology of severe lung injury

Researchers at the University of Illinois at Chicago College of Medicine have been awarded more than $11.7 million to study the pathology of severe lung injury.

30 Jul 2011

Anesthetic agent isoflurane may treat intracerebral hemorrhage

The anesthetic agent isoflurane may be a useful treatment for intracerebral hemorrhage (ICH)—a type of stroke caused by bleeding inside the brain, reports a study in the August issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

26 Jul 2011

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Baxter International Inc. announced today that the U.S. Food and Drug Administration has approved the subcutaneous administration of GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] for patients with primary immunodeficiency.

From Baxter International Inc. 25 Jul 2011

Edema News and Research

Further Reading

ONGLYZA used with insulin maintains improvement in glucose control in adults with type 2 diabetes

New collaboration reinforces Sanofi's translational discovery platform for retinal diseases

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Lucentis receives Health Canada approval to treat vision loss from DME

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

Astellas seeks regulatory approval for mirabegron to treat overactive bladder in the U.S., Europe

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

KalVista raises £8 million in series A round of funding

Lucentis receives Health Canada approval for treatment of retinal vein occlusion

HSS, pSivida enter orthopedic evaluation agreement

Dyax initiates ecallantide Phase 2 trial for ACE inhibitor-induced angioedema

NIH-funded study to assess biomarkers in the blood of TBI patients

Pharming, Santarus reach SPA agreement with FDA for RHUCIN Phase III trial

Conference to focus on connection between fluid balance and hypertension

Researchers awarded $12M to study pathology of severe lung injury

Anesthetic agent isoflurane may treat intracerebral hemorrhage

Baxter GAMMAGARD LIQUID for PI receives FDA approval for subcutaneous administration

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News